GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

verdinexor   Click here for help

GtoPdb Ligand ID: 14273

Synonyms: KPT-335 | KPT335
Compound class: Synthetic organic
Comment: Verdinexor (KPT-335) is an orally bioavailable selective inhibitor of nuclear export (SINE). It targets exportin 1 (XPO1) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 81.45
Molecular weight 442.32
XLogP 2.45
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=NC=C1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
Isomeric SMILES C1=CC=NC(=C1)NNC(=O)/C=C\N2C=NC(=N2)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
InChI InChI=1S/C18H12F6N6O/c19-17(20,21)12-7-11(8-13(9-12)18(22,23)24)16-26-10-30(29-16)6-4-15(31)28-27-14-3-1-2-5-25-14/h1-10H,(H,25,27)(H,28,31)/b6-4-
InChI Key OPAKEJZFFCECPN-XQRVVYSFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Verdinexor (KPT-335) was proposed principally for veterinary use in lymphoma treatment [2-4]. There are no active human studies listed on ClinicalTrials.gov (Nov. 2025).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02431364 Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults Phase 1 Interventional Karyopharm Therapeutics Inc